Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2017, Article ID 1924907, 7 pages
https://doi.org/10.1155/2017/1924907
Clinical Study

Myocardial Expression of PPARγ and Exercise Capacity in Patients after Coronary Artery Bypass Surgery

1Institute of Cardiology, Intensive Cardiac Therapy Clinic, Alpejska St. 42, 04-628 Warsaw, Poland
2Department of General and Experimental Pathology, Medical University of Bialystok, Mickiewicza St. 2c, 15-222 Bialystok, Poland
3Institute of Cardiology, Department of Cardiac Rehabilitation and Noninvasive Electrocardiology, Alpejska St. 42, 04-628 Warsaw, Poland
4Institute of Oncology, Department of Molecular and Translational Oncology, Wawelska St. 15B, 02-034 Warsaw, Poland

Correspondence should be addressed to Izabela Wojtkowska; lp.po@tjowalebazi

Received 30 May 2017; Revised 21 July 2017; Accepted 21 August 2017; Published 28 September 2017

Academic Editor: Qinglin Yang

Copyright © 2017 Izabela Wojtkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. P. Dhakal, R. Malhotra, R. M. Murphy et al., “Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction,” Circulation: Heart Failure, vol. 8, no. 2, pp. 286–294, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Arena, J. Myers, and M. Guazzi, “The clinical importance of cardiopulmonary exercise testing and aerobic training in patients with heart failure,” Revista Brasileira de Fisioterapia, vol. 12, no. 2, pp. 75–87, 2008. View at Google Scholar · View at Scopus
  3. D. Harrington, S. D. Anker, T. P. Chua et al., “Skeletal muscle function and its relation to exercise tolerance in chronic heart failure,” Journal of the American College of Cardiology, vol. 30, no. 7, pp. 1758–1764, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Drexler, U. Riede, T. Münzel, H. König, E. Funke, and H. Just, “Alterations of skeletal muscle in chronic heart failure,” Circulation, vol. 85, no. 5, pp. 1751–1759, 1992. View at Google Scholar · View at Scopus
  5. S. D. Anker, P. P. Ponikowski, A. L. Clark et al., “Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure,” European Heart Journal, vol. 20, no. 9, pp. 683–693, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Tsujinaka, C. Ebisui, J. Fujita et al., “Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse,” Biochemical and Biophysical Research Communications, vol. 207, no. 1, pp. 168–174, 1995. View at Google Scholar
  7. V. M. Conraads, E. M. Van Craenenbroeck, C. De Maeyer, A. M. Van Berendoncks, P. J. Beckers, and C. J. Vrints, “Unraveling new mechanisms of exercise intolerance in chronic heart failure. Role of exercise training,” Heart Failure Reviews, vol. 18, no. 1, pp. 65–77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. W. S. Lee and J. Kim, “Peroxisome proliferator-activated receptors and the heart: lessons from the past and future directions,” PPAR Research, vol. 2015, Article ID 271983, 18 pages, 2015. View at Publisher · View at Google Scholar
  9. D. Kamimura, K. Uchino, T. Ishigami, M. E. Hall, and S. Umemura, “Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism,” Journal of Cardiovascular Pharmacology, vol. 68, no. 2, pp. 155–161, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Shiomi, H. Tsutsui, S. Hayashidani et al., “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction,” Circulation, vol. 106, no. 24, pp. 3126–3132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Ito, A. Nakano, M. Kinoshita, and A. Matsumori, “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia/reperfusion injury in a rat model,” Laboratory Investigation, vol. 83, no. 12, pp. 1715–1721, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Honda, K. Kaikita, K. Tsujita et al., “Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 5, pp. 915–926, 2008. View at Google Scholar
  13. Y. Xu, M. Gen, L. Lu et al., “PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 288, no. 3, pp. H1314–H1323, 2005. View at Google Scholar
  14. C. A. Lygate, K. Hulbert, M. Monfared, M. A. Cole, K. Clarke, and S. Neubauer, “The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction,” Cardiovascular Research, vol. 58, no. 3, pp. 632–637, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. H.-W. Liao, J. L. Saver, Y.-L. Wu, T.-H. Chen, M. Lee, and B. Ovbiagele, “Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis,” BMJ Open, vol. 7, no. 1, Article ID e013927, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Yokota, S. Kinugawa, K. Hirabayashi et al., “Pioglitazone improves aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome,” Journal of Cardiac Failure, vol. 22, no. 9, p. S205, 2016. View at Publisher · View at Google Scholar
  17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, “ATS statement: guidelines for the six-minute walk test,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 1, pp. 111–117, 2002. View at Publisher · View at Google Scholar
  18. I. Wojtkowska, A. Tysarowski, K. Seliga et al., “PPAR gamma expression levels during development of heart failure in patients with coronary artery disease after coronary artery bypass-grafting,” PPAR Research, Article ID 242790, 242790 pages, 2014. View at Google Scholar
  19. C. Fiorina, E. Vizzardi, R. Lorusso et al., “The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme,” European Journal of Cardiothoracic Surgery, vol. 32, no. 5, pp. 724–729, 2007. View at Google Scholar
  20. N. H. Son, T. S. Park, H. Yamashita et al., “Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice,” Journal of Clinical Investigtion, vol. 11, no. 10, pp. 2791–2801, 2007. View at Google Scholar
  21. R. K. Vikramadithyan, K. Hirata, H. Yagyu et al., “Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy,” Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 2, pp. 586–593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Burke, S. Chang, H. Wakimoto et al., “Molecular profiling of dilated cardiomyopathy that progresses to heart failure,” JCI Insight, vol. 1, no. 6, 2016. View at Publisher · View at Google Scholar
  23. H. Cernecka, G. Doka, J. Srankova et al., “Ramipril restores PPARβ/δ and PPARγ expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat,” European Journal of Pharmacology, vol. 791, pp. 244–253, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Grewal, R. B. McCully, G. Kane, C. Lam, and P. A. Pellikka, “Left ventricular function and exercise capacity,” JAMA, vol. 301, no. 3, pp. 286–94, 2009. View at Google Scholar
  25. Y. Ye, Z. Hu, Y. Lin, C. Zhang, and J. R. Perez-Polo, “Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γ agonist protects against myocardial ischaemia–reperfusion injury,” Cardiovascular Research, vol. 87, no. 3, pp. 535–544, 2010. View at Publisher · View at Google Scholar
  26. A. Cabrero, J. C. Laguna, and M. Vázquez, “Peroxisome proliferator-activated receptors and the control of inflammation.,” Curr Drug Targets Inflamm Allergy, vol. 1, no. 3, pp. 243–248, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Gullestad, T. Ueland, L. E. Vinge, A. Finsen, A. Yndestad, and P. Aukrust, “Inflammatory cytokines in heart failure: mediators and markers,” Cardiology, vol. 122, no. 1, pp. 23–35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, and D. L. Mann, “Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST),” Circulation, vol. 103, no. 16, pp. 2055–2059, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Thierer, A. Acosta, N. Vainstein et al., “Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study),” American Journal of Cardiology, vol. 105, no. 7, pp. 977–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Fernandes-Silva, G. V. Guimarães, V. O. Rigaud et al., “Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: insights from a randomized clinical trial,” European Journal of Preventive Cardiology, vol. 24, no. 8, pp. 808–817, 2017. View at Publisher · View at Google Scholar
  31. P. Muñoz-Cánoves, C. Scheele, B. K. Pedersen, and A. L. Serrano, “Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?” The FEBS Journal, vol. 280, no. 17, pp. 4131–4148, 2013. View at Publisher · View at Google Scholar · View at Scopus